The Future of Animal Health

SustentoBio_Logo.png

SustentoBio Inc. is a veterinary biotechnology company dedicated to providing animals with the latest advancements in immunotherapeutics. Using a specially developed protein, our product is able to enhance the animal’s own immune system to fight solid tumors and infectious disease. The treatment is non-invasive, has no known side effects, is cost-effective, and is less painful than the current leading cellular treatment.

 

SUSTENTOBIO: MISSION

We believe pets should have access to the same type of therapies as humans … and at an affordable price.

SUSTENTOBIO: WHAT WE DO

Primary goals:

(1) to improve the quality of life for companion animals
(2) to extend the life expectancy of diseased animals

(3) to offer treatments at an affordable price

Indications:

Solid Tumors, Infectious Disease and Rejuvenation

MARKET: HUMANIZATION OF PETS

ペット

Over past two decades, dogs, cats and other companion animals have increasingly become an integral part of the family household.

​​

  • 67% of U.S. households, or about 85 million families own a pet.

  • 95% of owners consider pets part of their family.

  • In older populations, pets are providing companionship.

  • In young adult population, pets are replacing the desire to have children.

Greater focus is placed on improving the lifestyle and well-being of pets.

  • Greater frequency of visits to the veterinarian.

  • Increased spending on healthcare.

CURRENT CANCER TREATMENTS

iStock-579248574.jpg

Surgical Excision

  • Invasive

  • Cannot address advanced stage disease

Radiation Therapy

  • Requires specialized equipment, not readily available

  • Unpredictable results

Chemotherapy (CHOP Protocol)

  • Many side effects, including lethargy

  • Unpredictable results

Cost of Treatment: $3,000 to $10,000

Post-Treatment Survival: 6 months